- Lee RH, Roy R, Li H, Hechmer A, Zhu TR, Izgutdina A, Olshen AB, Johnson DE, Grandis JR. Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts. PLoS One, 2023, Mar 1;18(3):e0282177. doi: 10.1371/journal.pone.0282177. (PMID: 36857322; PMCID: PMC9977000)
- Shiah JV, Johnson DE, Grandis JR. Transcription factors and cancer: Approaches to targeting. Cancer Journal. 2023 Jan-Feb 01;29(1):38-46. doi: 10.1097/PPO.0000000000000639. (PMID: 36693157; PMCID: PMC9881838).
- Qureshy Z*, Li H*, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim M-O, Ryan WR, Ha PK, Bauman JE, Wang SJ, Long SR, Johnson DE, Grandis JR (*equal contributors). STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clinical Cancer Research, 2022, Nov 1;28(21):4737-4746. doi: 10.1158/1078-0432.CCR-22-0744. (PMID: 35929989)
- Guix I, Liu Q, Pujana MA, Ha P, Piulats J, Linares I, Guedea F, Mao JH, Lazar A, Chapman J, Yom SS, Ashworth A, Barcellos-Hoff MH. Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy. Clin Cancer Res. 2022 Apr 1;28(7):1372-1382. doi: 10.1158/1078-0432.CCR-21-2846.PMID: 35022323
- Humtsoe JO, Kim HS, Jones L, Cevallos J, Boileau P, Kuo F, Morris LGT, Ha P. Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma. Cancers (Basel). 2022 Apr 30;14(9):2263. doi: 10.3390/cancers14092263. PMID: 35565392.
- Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB; Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 Jan 6;185(1):184-203.e19. doi: 10.1016/j.cell.2021.12.004. Epub 2021 Dec 27.PMID: 34963056
- Li H, Peyser ND, Zeng Y, Ha PK, Johnson DE, Grandis JR. NSAIDs overcome PIK3CA mutation-mediated resistance to EGFR inhibition in head and neck cancer preclinical models. Cancers (Basel) Jan 20; 14(3):506. doi: 10.3390/cancers14030506. 2022 (PMID: 35158773).
- Long Z, Grandis JR, Johnson DE. Emerging tyrosine kinase inhibitors for head and neck squamous cell carcinoma. Expert Opinion on Emerging Drugs 2022 Sep;27(3):333-344. doi: 10.1080/14728214.2022.2125954. Epub 2022 Sep 21. (PMID: 36131561; PMCID: PMC9987561).
- Van Landingham NK, Nazarenko A, Grandis JR, Johnson DE. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. Advances in Biological Regulation 2022 Nov 15:100934. doi: 10.1016/j.jbior.2022.100934. Online ahead of print. (PMID: 36402737).
- Jin N, Keam B, Cho J, Lee M, Kim HR, Torosyan H, Jura N, Ng PK-S, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Kim M-O, Swaney DL, Krogan NJ, Johnson DE*, Grandis JR*. Therapeutic implications of activating non-canonical PIK3CA mutations in head and neck squamous cell carcinoma. Co-corresponding authors. Journal of Clinical Investigation Nov 15;131(22):e150335. doi: 10.1172/JCI150335. 2021 (PMID: 34779417; PMCID: PMC8592538)
- Warren BR, Grandis JR, Johnson DE, Villa A. Head and neck cancer among American Indian and Alaska Native populations in California. Cancers (Basel). Oct 16,13(20:5195. doi: 10.3390/cancers13205195. 2021 (PMID: 34680342; PMCID: PMC8534223)
- Bouhaddou M, Lee RH, Li H, Bhola NE, O’Keefe RA, Naser M, Zhu T, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, Mills GB, Vanderberg S, Swaney DL, Johnson DE, Krogan NJ, Grandis JR. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Journal of Clinical Investigation Insight Sep 21; e151982. doi:10.1172/jci.insight.151982. Online ahead of print. 2021 (PMID: 34546978; PMCID: PMC8564908)
- Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O’Keefe R, Jin N, VanLandingham NK, Foussard H, Von Dollen J, Bouhaddou M, Jimenez-Morales D, Obernier K, Kreisberg JF, Kim M, Johnson DE, Jura N, Grandis JR, Gutkind JS, Ideker T, Krogan NJ. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science Oct;374(6563):eabf2911. doi:10.1126/science.abf2911. Epub Oct 1, 2021 (PMID: 34591642)
- Cui Z, Dabas H, Leonard BC, Shiah JV, Grandis JR, Johnson DE. Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death and Disease doi: 10.1038/s41419-021-04066-z, Aug 6, 2021 (PMID: 34362880; PMCID: PMC8346537)
- Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AM. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 Dec;43(12):3875-3887. doi: 10.1002/hed.26885. Epub 2021 Oct 9.PMID: 34626024
- Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau HY, Licitra L, Moore MG, Rodriguez C, Roshal A, Seethala R, Swiecicki P, Ha P. Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol. 2021 Jun 10;39(17):1909-1941. doi: 10.1200/JCO.21.00449. Epub 2021 Apr 26.PMID: 33900808
- Humtsoe JO, Kim HS, Leonard B, Ling S, Keam B, Marchionni L, Afsari B, Considine M, Favorov AV, Fertig EJ, Kang H, Ha PK. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021 Feb 15;81(4):1001-1013. doi: 10.1158/0008-5472.CAN-20-1780. Epub 2021 Jan 6.PMID: 33408119
- Bhola NE*, Njatcha C*, Hu L, Lee ED, Shiah JV, Kim M-O, Johnson DE, Grandis JR (*equal contributors). PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head and Neck doi: 10.1002/hed.26827. Online ahead of print, Aug 3, 2021 (PMID: 34346116; PMCID: PMC8664160)
- Cui Z, Kang H, Grandis JR, Johnson DE. CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers. Molecular Cancer Research 19(1):14-24, 2021 (PMID: 32883697; PMC7840145)
- Shiah JV, Grandis JR, Johnson DE. Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides. Molecular Cancer Therapeutics 20(2):219-228, 2021 (PMID: 33203730; PMCID: PMC7888537)
- Geiger JL, Cedars ED, Zang Y, Normolle DP, Li H, Grandis JR, Centuori S, Johnson DE, Bauman JE. Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield. Laryngoscope Investigative Otolaryngology Jan 18;6(1):116-121, 2021 (PMID: 33614939; PMCID: PMC7883625)
- Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR. Treatment of Fanconi anemia-associated head and neck cancer: opportunities to improve outcomes. Clinical Cancer Research May 27, 2021 (PMID: 34045293; PMCID: PMC8626541)
- Park S, Vora M, van Zante A, Humtsoe J, Kim HS, Yom S, Agarwal S, Ha P. Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma. J Otolaryngol Head Neck Surg. 2020 Jul 10;49(1):48. doi: 10.1186/s40463-020-00446-1.PMID: 32650834
- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers Nov 26; 6(1):92. doi: 10.1038/s41572-020-00224-3, 2020 (PMID: 33243986; PMCID: PMC7944998)
- Ramasamy T, Chen X, Qin B, Johnson DE, Grandis JR, Villanueva FS. STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. PLos One Nov 18;15(11):e0242264. doi: 10.1371/journal.pone.0242264, 2020 (PMID: 33206698; PMCID: PMC7673576)
- Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS. Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 19:1562-1571, 2020 (PMID: 32430488; PMCID: PMC7357849)
- O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One. 2020; 15(1):e0227261. (PMID: 31914141. PMCID: PMC6948745)
- Lee MJ, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118679. doi: 10.1016/j.bbamcr.2020.118679. Epub 2020 Feb 19. (PMID: 32061630; PMCID: PMC7671657)
- Qureshy Z, Johnson DE, Grandis JR. Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment. 6:27. Epub Aug 21, 2020 (PMID: 33521321; PMCID: PMC7845926)
- Cai Y, Yousef A, Grandis JR, Johnson DE. NSAID therapy for PIK3CA-altered colorectal, breast, and head and neck cancer. Advances in Biological Regulation 2020 Jan;75:100653. doi: 10.1016/j.jbior.2019.100653. Epub 2019 Sep 15. (PMID: 31594701; PMCID: PMC7056575)
- Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.PMID: 31483290
- Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Mol Med Rep. 2019 Dec; 20(6):5335-5344. (PMID: 31661135. PMCID: PMC6854598)
- Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncol. 2019 08; 95:35-42. (PMID: 31345392. PMCID: PMC6827881)
- Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Chronic non-steroidal anti-inflammatory drug use predicts improved survival for PIK3CA-altered head and neck cancer. Journal of Experimental Medicine 216(2):419-427, 2019 (PMID: 30683736; PMCID: PMC6363423)
- Sola AM, Johnson DE, Grandis JR. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion Investigational Drugs 28(4):351-363, 2019 (PMID: 30753792; PMCID: PMC6857634)
- Lau K, Ramaiyer M, Johnson DE, Grandis JR. Targeting STAT3 with nucleotide therapeutics. Cancers (Basel) 2019 Oct 29;11(11). Pii: E1681. doi: 10.3390/cancers11111681. (PMID: 31671769; PMCID: PMC6896109).
- Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha PK, Murnane J, Cuartas I, Seoane J, Baumann M, Linge A, Barcellos-Hoff MH.Clin Cancer Res. Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. 2018 Dec 1;24(23):6001-6014. doi: 10.1158/1078-0432.CCR-18-1346. Epub 2018 Aug 7.PMID: 30087144
- Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25.PMID: 29942093
- Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nature Reviews Clinical Oncology 15:234-248, 2018. (PMID: 29405201; PMCID: PMC5858971)
- Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. Int J Mol Sci. 2018 May 30; 19(6). Pii:E1608, doi:10.3390/ijms19061608. (PMID: 29848966. PMCID: PMC6032396)
- Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. STAT3 cyclic decoy demonstrates robust antitumor effects in non-small cell lung cancer. Molecular Cancer Therapeutics 17(9):1917-1926, Jun 11, 2018. (PMID: 29891486; PMCID: PMC6125196)
- Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. A Phase I study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia and Lymphoma 59(11):2595-2601, 2018. (PMID: 29616864; PMCID: PMC6201295)
- Cho J, Johnson DE, Grandis JR. Therapeutic implications of the genetic landscape of head and neck cancer. Seminars in Radiation Oncology 28(1):2-11, 2018. (PMID: 29173752; PMCID: PMC6293987)
- Leonard BC and Johnson DE. Signaling by cell surface death receptors: Alterations in head and neck cancer. Advances in Biological Regulation 67:170-178, 2018. (PMID: 29066276; PMCID: PMC5854325)
- Kemmer JD, Johnson DE, Grandis JR. Leveraging genomics for head and neck cancer treatment. Journal of Dental Research 97(6):603-613, 2018. (PMID: 294420101; PMCID: PMC5960879)
- Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer. Trends in Cancer 4(5):385-396, 2018. (PMID: 29709262; PMCID: PMC6226306)
- Lee YS, Johnson DE, Grandis JR. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs 23(4):283-299, 2018 (PMID: 30376740; PMCID: PMC6525082)
- Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer and Metastasis Review 36:463-473, 2017. (PMID: 28866730; PMCID: PMC5693744)
- Guo T, Sakai A, Afsari B, Considine M, Danilova L Favorov AV, Yegnasubramanian S, Kelley D, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, and Califano J. Definition of alternative splice expression in human papillomavirus-related oropharyngeal cancer includes a novel functional splice variant of AKT3. Cancer Research. 2017 Oct 1;77(19):5248-5258. Jul 21 [Epub ahead of print].
- Johnson DE, Bauman JE. When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. Cancer Prevention Research (Phila). 2017 Sep; 10(9):489-490.
- Kang H, Tan M, Bishop JA, Jones S, Sausen M, Ha PK, Agrawal N. Whole exome sequencing of salivary gland mucoepidermoid carcinoma. Clin Cancer Res. 2017 jan 1;23(1):283-288. Epub 2016 Jun 23.
- Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research (Phila). 2016 Jul; 9(7):547-57.
- Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS One. 2016; 11(11):e0166185. (PMID: 27855189. PMCID: PMC5113908)
- Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Aug; 9(8):657-63.
- Ling S, Rettig EM, Tan M, Chang X, Wang Z, Brait M, Bishop JA, Fertig EJ, Considine M, Wick MJ, Ha PK. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. Int J Oncol. 2016 Jul; 49(1); 225-34. Epub May 18.
- Rettig EM, Talbot C, Sausen M, Jones S, Bishop JA, Wood LD, Tokheim C, Niknafs N, Karchin R, Fertig E, Wheelan S, Marchionni L, Considine M, Fakhry C, Papadopoulos N, Kinzler KW, Vogelstein B*, Ha PK*, Agrawal N*. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res (Phila). 2016 Apr;9(4)265-74. Epub Feb 9. *co-corresponding authors
- Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2016 Mar 03; 35(9):1163-9.
- Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016 Jan; 126(1):169-80.
- Rettig EM, Tan M, Ling S, Yonescu R, Bishop J, Fakhry C, Ha PK. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope, 2015 Sep; 125(9): E292-9.
- Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44.
- Wang Z, Ling S, Rettig E, Sobel R, Tan M, Fertig EJ, Considine M, El-Naggar AK, Brait M, Fakhry C, Ha PK. Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration. Oral Oncology, 2015 Dec;51(12):1120-5. Epub 2015 Oct 15.
- Rettig EM, Tan M, Ling S, Yonescu R, Bishop J, Fakhry C, Ha PK. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope, 2015 Sep; 125(9): E292-9.
- Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Molecular Oncology. 2014 Oct; 8(7):1220-30.
- Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1114-9.
- Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncology 2014 Feb; 50(2):120-7.
- Zang Y, Kirk CJ, and Johnson DE. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biology and Therapy 2014; 15(9):1142-1152.
- Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul; 3(7):761-9.
- Li C and Johnson DE. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle 2013; 12:923-934.
- Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research 2012 Oct 15; 18(20):5639-49.
- Shao C, Tan M, Bishop JA, Liu J, Bai W, Gaykalova DA, Ogawa T, Vikani AR, Agrawal Y, Li RJ, Kim MS, Westra WH, Sidransky D, Califano JA, Ha PK. Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PLoS One, 2012;7(11):e48582. Epub 2012 Nov 12.
- Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012 Aug; 2(8):694-705.
- Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012 Dec; 8(12):1873-4
- Li C and Johnson DE. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Letters 2012; 314:102-107.
- Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
- Shao C, Sun W, Tan M, Glazer CA, Bhan S, Zhong X, Fakhry C, Sharma R, Westra WH, Hoque MO, Moskaluk CA, Sidransky D, Califano JA, and Ha PK. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clinical Cancer Research. 2011 Jul 1;17(13):4320-30. Epub 2011 May 6.
- Shao C, Bai W, Junn JC, Uemura M, Hennessey PT, Zaboli D, Sidransky D, Califano JA, and Ha PK. Evaluation of Myb promoter methylation in salivary adenoid cystic carcinoma. Oral Oncol. 2011 Apr;47(4):251-5. Epub 2011 Feb 15.
- Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011 Feb; 4(2):230-7.
- Durr ML, Mydlarz WK, Shao C, Zahurak M, Chuang AY, Hoque MO, Westra WH, Liegeois NJ, Califano JA, Sidransky D, and Ha PK. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One. 2010 May 26;5(5):e10828.
- Kropf PL, Wang L, Zang Y, Redner RL, and Johnson DE. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 2010; 24:663-665.
- Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol. 2009 Mar 10; 27(8):1235-42.
- Jones JE, Wang L, Kropf PL, Duan R, and Johnson DE. Src family kinase gene targets during myeloid differentiation: Identification of the EGR-1 gene as a direct target. Leukemia 2009; 23:1933-1935.
- Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Molecular Pharmacology 2009 May; 75(5):1231-9.
- Mithani SK, Shao C, Tan M, Smith IM, Califano JA, El-Naggar AK, and Ha PK. Mitochondrial mutations in adenoid cystic carcinomas of the salivary glands. PLoS One, 2009;4(12);e8493.
- Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics 2009 Aug; 8(8):2211-20.
- Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A. 2006 May 02; 103(18):6901-6.
- Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005 Feb 03; 24(6):970-9.
- Ha PK, Benoit NE, Westra WH, Sciubba JJ, Califano JA. A transcriptional progression model for head and neck cancer using expression microarrays. Clin Cancer Res. 2003 Aug 1;9(8):3058-64.
- Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):4138-43.
- Ha PK, Pai SI, Westra WH, Gillison ML, Tong BC, Sidransky D, Califano JA. Real time quantitative PCR demonstrates low prevalence of human papillomavirus Type 16 in Premalignant and Malignant Lesions of the Oral Cavity. Clinical Cancer Research. 2002 May; 8(5): 1203-9.